Publication

EHA •
14 June, 2024 •
•

A Phase 3, Randomised, Double-Blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia (AVA-PED-301)

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Jessica Zhang, Linda Smallwood, Emily de León, Brian D. Jamieson

Available materials

Oral Presentation

Publication

EHA •
14 June, 2024 •
•

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

Srikanth Nagalla, My Levy, Shruti Chaturvedi, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg , Scott Kolodny

Publication

EHA •
14 June, 2024 •
•

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Francesco Zaja, Quentin Hill, Fiona Glen, Fatemeh Saberi Hosnijeh, Luca Le Treust, Lara Groves, Milica Putnik, Carly Rich

Publication

EHA •
14 June, 2024 •
•

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

Srikanth Nagalla, Cecilie Yssing, Donatella Decise, Milica Putnik, Carly Rich

Publication

Characterization of clinically significant breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan

A Phase 3, Randomised, Double-Blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia (AVA-PED-301)

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults

Analysis of Baseline Influences on Platelet Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Pati

Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure

Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration